Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2Sarcoma 1NET 1

Conditions

Glioma 8Glioblastoma 7Recurrence 3Osteosarcoma 3Neuroblastoma 3Medulloblastoma 3Ependymoma 3Central Nervous System Neoplasms 3Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Xanthogranuloma, Juvenile 1Sarcoma, Synovial 1Sarcoma, Ewing 1Neuroendocrine Tumors 1Meningioma 1Histiocytic Sarcoma 1Gliosarcoma 1Familial ependymoma 1Esthesioneuroblastoma, Olfactory 1Breast Neoplasms 1

Interventions

3-Iodobenzylguanidine 8lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Paraganglioma × olaparib × CNS × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡